ArticleMethods in molecular biology (Clifton, N.J.)2025
In Situ and In Silico Methods for Senescence Identification in Human Liver Diseases.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overview of molecular signatures of senescence and associated resources: pros and cons.FEBS open bio · 2026Review
- Immune cell senescence drives responsiveness to immunotherapy in melanoma.Molecular cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence and aging are two distinct but overlapping entities that are both characterized by the intracellular accumulation of lipofuscin, the "dark" matter of the cell. Tissues like liver composed of slow dividing cells are prone to lipofuscin accumulation, thus creating an interesting intersection between aging and senescence. In the current work, we propose two approaches for the discrimination of these entities. The first one regards the adjustment of an established in situ senescence detecting algorithm in human liver diseases. The second one is based on a novel senescence molecular signature that can be applied, solely or complementary, to the in situ algorithm, in RNA data from the above clinical settings for in silico identification of cellular senescence.
Indexed as
Identifiers
40082347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.